Mirxes Holding Company Limited Secures Landmark Government Project for Gastric Cancer Screening in China

Key Highlights of the Announcement

• Mirxes Holding Company Limited has successfully won the bid for the 2026 Lianxi District Gastric Cancer Screening and Early Intervention Project.
• This marks the Company’s first public health early cancer screening programme and its first government procurement project in China.
• The project is valued at up to RMB 7.695 million within a total budget of RMB 8.1 million.
• The programme will provide early gastric cancer screening services for approximately 30,000 residents in Lianxi District, which constitutes about 8% of its total population.
• This initiative represents the largest public health gastric cancer early screening programme in the region, targeting a district with a high incidence of gastric cancer.
• The project leverages Mirxes’ proprietary miRNA liquid biopsy technology through its core product, GASTROClear™.
• GASTROClear™ is the first in vitro diagnostic product for gastric cancer screening in China approved as a Class III Medical Device.
• The Company aims to use this project as a model for broader adoption and future government procurement opportunities in China.

In-Depth Details for Investors

On March 3, 2026, Mirxes Holding Company Limited announced its successful bid for the 2026 Lianxi District Gastric Cancer Screening and Early Intervention Project. This contract is highly significant as it marks the Company’s formal entry into China’s public healthcare system, utilizing its miRNA liquid biopsy technology. The project serves as a strategic milestone, laying the groundwork for the large-scale implementation of early gastric cancer screening and intervention in China.

Project Scope and Strategic Importance

• The project will deliver screening services to approximately 30,000 residents, covering about 8% of Lianxi District’s population of 418,000.
• Lianxi District is located in Jiujiang, Jiangxi Province, a region with high gastric cancer risk due to dietary habits (high-salt and marinated foods) and a high prevalence of Helicobacter pylori infection.
• The initiative is expected to boost local early detection rates and reinforce the region’s cancer prevention framework, directly addressing the high disease burden caused by late-stage diagnoses.

Why This Project is Price Sensitive for Shareholders

• This is Mirxes’ first major government-backed project in China, potentially opening doors to new revenue streams and large-scale public health contracts.
• Successful execution may position the Company as a market leader in early cancer screening and could significantly enhance its reputation and commercial footprint in China’s vast healthcare market.
• The project will allow the Company to gain valuable operational experience in China’s government procurement process, facilitating future bids and expansion.
• The Company’s GASTROClear™ technology is recognized for its non-invasive, accurate, and efficient screening, offering a scalable solution for early cancer detection. This approval and adoption may boost investor confidence in the Company’s R&D and commercialization capabilities.

Product and Market Details

• GASTROClear™ is the first blood-based in vitro diagnostic tool for gastric cancer screening in China, filling a critical gap left by low compliance to endoscopy and limited accuracy of traditional tumor markers.
• The Company’s technology is well-suited for large-scale, population-level screening, aligning with China’s public health needs.
• The Board sees this project as a stepping stone for broader implementation of similar screening programmes across China, thereby supporting national cancer prevention and control strategies.

Operational and Commercial Milestones

• The project will help establish a “screening — diagnosis — intervention — follow-up” model for cancer prevention in Lianxi District.
• It represents a significant transition of the Company’s research and development achievements into practical, revenue-generating public health solutions.
• If successful, the project could catalyze further adoption of Mirxes’ products and technology in other regions and future government health initiatives.

Board of Directors and Leadership

• Dr. Zhou Lihan, Executive Director and Chief Executive Officer, leads the Company, supported by a diverse team of executive and non-executive directors.

Cautionary Note for Investors

Important: While this announcement is a significant positive development, investors should note that there is no assurance GASTROClear™ will be commercialized at scale. The Company’s future performance will depend on successful implementation and further adoption of its technology.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult professional advisors before making investment decisions. The information is based on the latest voluntary disclosure by Mirxes Holding Company Limited as of March 5, 2026. Market conditions and company performance may change, affecting future outcomes.

View MIRXES-B Historical chart here